Citations for
1OSMR, SHC1
Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor.
Persson E, Souza PPC, Floriano-Marcelino T, Conaway HH, Henning P, Lerner UH.
Front Immunol 10:1164. doi: 10.3389/fimmu.2019.01164. eCollection 2019. 2019
2CXCL12, OSMR
Oncostatin M Mediates Adipocyte Expression and Secretion of Stromal-Derived Factor 1.
Hang H, Bailey JL, Elks CM.
Biology (Basel) 8(1). pii: E19. doi: 10.3390/biology8010019. 2019
3OSMR
The role of oncostatin M receptor gene polymorphisms in bladder cancer.
Deng S, He SY, Zhao P, Zhang P.
World J Surg Oncol 17(1):30. doi: 10.1186/s12957-018-1555-7. 2019
4GFAP, OSMR, SMARCA4, STAT3
Gfap and Osmr regulation by BRG1 and STAT3 via interchromosomal gene clustering in astrocytes.
Ito K, Noguchi A, Uosaki Y, Taga T, Arakawa H, Takizawa T.
Mol Biol Cell 29(2):209-219. doi: 10.1091/mbc.E17-05-0271. Epub 2017 Nov 15. 2018
5OSMR
OSMR gene effect on the pathogenesis of chronic autoimmune Urticaria via the JAK/STAT3 pathway.
Luo XY, Liu Q, Yang H, Tan Q, Gan LQ, Ren FL, Wang H.
Mol Med 24(1):28. doi: 10.1186/s10020-018-0025-6. 2018
6OSM, OSMR
Oncostatin M Confers Neuroprotection against Ischemic Stroke.
Guo S, Li ZZ, Gong J, Xiang M, Zhang P, Zhao GN, Li M, Zheng A, Zhu X, Lei H, Minoru T, Li H.
J Neurosci 35(34):12047-62. doi: 10.1523/JNEUROSCI.1800-15.2015. 2015
7IL31, OSM, OSMR
Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology.
Hermanns HM.
Cytokine Growth Factor Rev ytokine Growth Factor Rev. 2015 Jul 3. pii: S1359-6101(15)00054-4. doi: 10.1016/j.cytogfr.2015.07.006. [Epub ahead of print] Rev 2015
8FPLCA, OSMR
A novel missense mutation in oncostatin M receptor beta causing primary localized cutaneous amyloidosis.
Saeedi M, Ebrahim-Habibi A, Haghighi A, Zarrabi F, Amoli MM, Robati RM.
Biomed Res Int 2014:653724. doi: 10.1155/2014/653724. Epub 2014 Jun 26. 2014
9OSMR
Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.
Caffarel MM, Chattopadhyay A, Araujo AM, Bauer J, Scarpini CG, Coleman N.
J Pathol 231(2):168-79. doi: 10.1002/path.4222. 2013
10LIFR, OSMR
A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor.
Chollangi S, Mather T, Rodgers KK, Ash JD.
J Biol Chem 287(39):32848-59. Epub 2012 Jul 24. 2012
11OSMR
Methylation of OSMR gene is frequently observed in non-invasive colorectal cancer.
Hibi K, Goto T, Sakuraba K, Shirahata A, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y.
Anticancer Res 31(4):1293-5. 2011
12FPLCA, OSMR
The molecular skin pathology of familial primary localized cutaneous amyloidosis.
Tanaka A, Lai-Cheong JE, van den Akker PC, Nagy N, Millington G, Diercks GF, van Voorst Vader PC, Clements SE, Almaani N, Techanukul T, Hide M, South AP, McGrath JA.
Exp Dermatol 19(5):416-23. doi: 10.1111/j.1600-0625.2010.01083.x. 2010
13FPLCA, OSMR
Oncostatin M Receptor-beta Mutations Underlie Familial Primary Localized Cutaneous Amyloidosis.
Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, Odashiro M, Odashiro DN, Hans-Neto G, Hans NR, Holder MV, Bhogal BS, Hartshorne ST, Akiyama M, Shimizu H, McGrath JA.
Am J Hum Genet 82(1):73-80. 2008
14BASP1, BRD9, DROSHA, NDUFS6, NNT, OSMR, PAIP1, PAPD7, RAD1, SDHA, SKP2, TARS
Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha.
Scotto L, Narayan G, Nandula SV, Subramaniyam S, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Schneider A, Arias-Pulido H, Murty VV.
Mol Cancer 7:58. 2008
15OSMR, OSM
Molecular and functional characterization of a soluble form of oncostatin M/interleukin-31 shared receptor.
Diveu C, Venereau E, Froger J, Ravon E, Grimaud L, Rousseau F, Chevalier S, Gascan H.
J Biol Chem 281(48):36673-82. Epub 2006 Oct 6. 2006
16ENC1, LIFRAS, LIFR, HEXB, GFM2, OSMR
Disruption of a novel ectodermal neural cortex 1 antisense gene, ENC-1AS and identification of ENC-1 overexpression in hairy cell leukemia.
Hammarsund M, Lerner M, Zhu C, Merup M, Jansson M, Gahrton G, Kluin-Nelemans H, Einhorn S, Grander D, Sangfelt O, Corcoran M.
Hum Mol Genet 13(23):2925-36. Epub 2004 Sep 30. 2004
17OSMR
Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.
Savarese TM, Campbell CL, McQuain C, Mitchell K, Guardiani R, Quesenberry PJ, Nelson BE.
Cytokine 17(6):324-34. 2002
18OSMR
Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression.
Radtke S, Hermanns HM, Haan C, Schmitz-Van De Leur H, Gascan H, Heinrich PC, Behrmann I.
J Biol Chem 277(13):11297-305. Epub 2002 Jan 10. 2002
19OSMR
Regulation of the type II oncostatin M receptor expression in lung-derived epithelial cells.
Cichy J, Rose-John S, Pure E.
FEBS Lett 429(3):412-6. 1998
20OSMR
Signaling of type II oncostatin M receptor.
Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-BarthelaixA, Gascan H.
J Biol Chem 272(25):15760-4. 1997
21OSMR
Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation.
Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D.
J Biol Chem 271(51):32635-43. 1996